Efficacy and Safety Comparison of Letermovir versus Valganciclovir for Use in Cytomegalovirus Prophylaxis in Adult Kidney Transplant Recipients (WTC 2025) - Jul 30, 2025 - Abstract #P2.05.27; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "Similar rates of CMV viremia and disease observed in patients on VCG and VCG converted to LTV with no impact on resistance or other outcomes. Conversion to LTV improved neutropenia and reduced use of GCSF. LTV can be safely used in high and moderate CMV risk KTR and requires FK dose adjustment upon initiation and discontinuation of LTV with close monitoring."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Leukopenia • Neutropenia • Solid Organ Transplantation • Transplantation
|
|
A. Russo 1; D. Pierce 1; R. Christensen 1; L. Heinrich 1; B. Valdepenas 1; L. Gallon 2; E. Benedetti 3; I. Tzvetanov 3; C. Muran 1
|